FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Susan Slovin

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Living Beings

Human Herpesvirus 4

Co-author Network

Publications

TOP 3
Susan F Slovin; William Olson; Howard I Scher; Robert Durso; Celina Fernandez; Jian P Gao; Robert Israel; Marissa Kehoe; Stephen Morris
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.
Michael J Morris; Roberto Pili; Dana Elizabeth Rathkopf; Howard I Scher; Susan F Slovin; M Vincent; J J Chudow; Samuel R Denmeade; Mario A Eisenberger; J Farrelly; Michael A Carducci
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.
Gopa Iyer; Steven M Larson; Michael J Morris; Dana Elizabeth Rathkopf; Neal Rosen; Howard I Scher; Lawrence H Schwartz; Susan F Slovin; Tracy Curley; Anthony Delacruz; Merrill J Egorin; Glenn Heller; S Percy Ivy; Macaulay Steers; Qing Ye; David B Solit
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Susan Slovin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Susan F Slovin; William Olson; Howard I Scher; Robert Durso; Celina Fernandez; Jian P Gao; Robert Israel; Marissa Kehoe; Stephen Morris
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.
Vaccine 2013;31(6):943-9.
2012: Michael J Morris; Roberto Pili; Dana Elizabeth Rathkopf; Howard I Scher; Susan F Slovin; M Vincent; J J Chudow; Samuel R Denmeade; Mario A Eisenberger; J Farrelly; Michael A Carducci
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(10):2714-9.
2012: Gopa Iyer; Steven M Larson; Michael J Morris; Dana Elizabeth Rathkopf; Neal Rosen; Howard I Scher; Lawrence H Schwartz; Susan F Slovin; Tracy Curley; Anthony Delacruz; Merrill J Egorin; Glenn Heller; S Percy Ivy; Macaulay Steers; Qing Ye; David B Solit
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Cancer chemotherapy and pharmacology 2012;69(4):1089-97.
2011: Susan F Slovin
Are we trumping bone disease in prostate cancer?
Oncology (Williston Park, N.Y.) 2011;25(14):1390, 1393.
2011: Dana Elizabeth Rathkopf; Glenn Liu; Michael A Carducci; Mario A Eisenberger; Aseem Anand; Michael J Morris; Susan F Slovin; Yasutsuna Sasaki; Shunji Takahashi; Seiichiro Ozono; Nga Kit Eliza Fung; Shinta Cheng; Jinping Gan; Marco Gottardis; Mary T Obermeier; Jyotsna Reddy; S Zhang; Blisse J Vakkalagadda; Leila Alland; George Wilding; Howard I Scher
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(4):880-7.
2010: Andrew J Roth; Christian J Nelson; Barry Rosenfeld; Howard I Scher; Susan F Slovin; Michael J Morris; Noelle O'Shea; Gabrielle Arauz; William Breitbart
Methylphenidate for fatigue in ambulatory men with prostate cancer.
Cancer 2010;116(21):5102-10.
2010: Xingxing Zang; Peggy S Sullivan; Robert A Soslow; Rebecca Waitz; Victor E Reuter; Andrew Wilton; Howard T Thaler; Manonmani Arul; Susan F Slovin; Joyce Wei; David Spriggs; Jakob Dupont; James P Allison
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010;23(8):1104-12.
2010: Susan F Slovin
A clinical trials outcome paradox: should survival prevail in the absence of clinical benefit?
Immunotherapy 2010;2(2):155-8.
2010: Mayu O Frank; Julia Kaufman; Suyan Tian; Mayte Suárez-Fariñas; Salina Parveen; Nathalie E Blachère; Michael J Morris; Susan F Slovin; Howard I Scher; Matthew L Albert; Robert B Darnell
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer.
PloS one 2010;5(9):.
2009: Susan F Slovin; W Kevin Kelly; Andrew Wilton; Michael Kattan; Patricia L Myskowski; John Mendelsohn; Howard I Scher
Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.
Clinical genitourinary cancer 2009;7(3):E77-82.
2009: Michael J Morris; Daisy Huang; W Kevin Kelly; Susan F Slovin; Ryan D Stephenson; Caitlin Eicher; Anthony Delacruz; Tracy Curley; Lawrence H Schwartz; Howard I Scher
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.
European urology 2009;56(2):237-44.
2009: Michael J Morris; Neeta Pandit-Taskar; Jorge Carrasquillo; Chaitanya R Divgi; Susan F Slovin; W Kevin Kelly; Dana Elizabeth Rathkopf; Gretchen A Gignac; David B Solit; Lawrence H Schwartz; Ryan D Stephenson; Christina Hong; Anthony Delacruz; Tracy Curley; Glenn Heller; Xiaoyu Jia; Joseph A O'Donoghue; Steven M Larson; Howard I Scher
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(15):2436-42.
2009: Michael J Morris; Ethan Basch; George Wilding; Maha Hussain; Michael A Carducci; Celestia S Higano; Philip Kantoff; William K Oh; Eric J Small; Daniel George; Paul Mathew; Tomasz M Beer; Susan F Slovin; Charles Ryan; Christopher Logothetis; Howard I Scher
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
Clinical genitourinary cancer 2009;7(1):51-7.
2008: Nicholas Mitsiades; Denise D Correa; Cary P Gross; Arti Hurria; Susan F Slovin
Cognitive effects of hormonal therapy in older adults.
Seminars in oncology 2008;35(6):569-81.
2008: Arti Hurria; Susan F Slovin
Cancer in older adults: the oncologist's bread and butter.
Seminars in oncology 2008;35(6):560.
2008: R Houston Thompson; Xingxing Zang; Christine M Lohse; Bradley C Leibovich; Susan F Slovin; Victor E Reuter; John C Cheville; Michael L Blute; Paul Russo; Eugene D Kwon; James P Allison
Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage.
Cancer research 2008;68(15):6054-8.
2008: Steven Q Wang; Patricia S Mecca; Patricia L Myskowski; Susan F Slovin
Scrotal and penile papules and plaques as the initial manifestation of a cutaneous metastasis of adenocarcinoma of the prostate: case report and review of the literature.
Journal of cutaneous pathology 2008;35(7):681-4.
2008: Dana Elizabeth Rathkopf; Michael A Carducci; Michael J Morris; Susan F Slovin; Mario A Eisenberger; Roberto Pili; Samuel R Denmeade; Moshe Kelsen; Tracy Curley; Melinda Halter; Connie Collins; Martin Fleisher; Glenn Heller; Sharyn D Baker; Howard I Scher
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(18):2959-65.
2008: Matthew D Galsky; Mario A Eisenberger; Sandra Moore-Cooper; W Kevin Kelly; Susan F Slovin; Anthony Delacruz; Yih Lee; Iain J Webb; Howard I Scher
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2147-54.
2008: Susan F Slovin
Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?
Expert review of anticancer therapy 2008;8(3):465-74.
2008: Susan F Slovin
Pitfalls or promise in prostate cancer immunotherapy-which is winning?
Cancer journal (Sudbury, Mass.) 2008;14(1):26-34.
2007: Susan F Slovin
Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.
Clinical advances in hematology & oncology : H&O 2007;5(12):972-80.
2007: Michael J Morris; W Kevin Kelly; Susan F Slovin; Charles Ryan; Caitlin Eicher; Glenn Heller; Howard I Scher
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
The Journal of urology 2007;178(6):2378-83; discussion 2383-4.
2007: Susan F Slovin; Govind Ragupathi; Celina Fernandez; Meghan Diani; Matthew P Jefferson; Andrew Wilton; W Kevin Kelly; Michael J Morris; David B Solit; Henrik Clausen; Philip O Livingston; Howard I Scher
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".
Cancer immunology, immunotherapy : CII 2007;56(12):1921-30.
2007: Susan F Slovin
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Nature clinical practice. Oncology 2007;4(9):551-4.
2007: Michael J Morris; Neeta Pandit-Taskar; Chaitanya R Divgi; Samantha Bender; Joseph A O'Donoghue; Angelo Nacca; Peter Smith-Jones; Lawrence H Schwartz; Susan F Slovin; Ronald Finn; Steven M Larson; Howard I Scher
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2707-13.
2007: David B Solit; S Percy Ivy; Catherine Kopil; Rachel Sikorski; Michael J Morris; Susan F Slovin; W Kevin Kelly; Anthony Delacruz; Tracy Curley; Glenn Heller; Steven M Larson; Lawrence H Schwartz; Merrill J Egorin; Neal Rosen; Howard I Scher
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1775-82.
2007: Susan F Slovin
Emerging role of immunotherapy in the management of prostate cancer.
Oncology (Williston Park, N.Y.) 2007;21(3):326-33; discussion 334, 338, 346-8.
2006: David Feltquate; Luke Nordquist; Caitlin Eicher; Michael J Morris; Oren Smaletz; Susan F Slovin; Tracy Curley; Andrew Wilton; Martin Fleisher; Glenn Heller; Howard I Scher
Rapid androgen cycling as treatment for patients with prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7414-21.
2006: Andrew J Roth; Christian J Nelson; Barry Rosenfeld; Adam Warshowski; Noelle O'Shea; Howard I Scher; Jimmie C Holland; Susan F Slovin; Tracy Curley-Smart; Thomas Reynolds; William Breitbart
Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC).
Psychosomatics 2006;47(4):340-7.
2006: Michael D Stubblefield; Susan F Slovin; Barbara MacGregor-Cortelli; J Muzzy; Howard I Scher; John Wright; Dixie Esseltine; David P Schenkein; Owen A O'Connor
An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2006;18(5):410-8.
2006: Susan F Slovin
Immunologic targeting: how to channel a minimal response for maximal outcome.
Current opinion in urology 2006;16(3):179-85.
2006: Susan F Slovin
Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?
Nature clinical practice. Urology 2006;3(3):138-44.
2006: Susan F Slovin; Matthew D Galsky; Klaus J Busam
Violaceous exanthem as a manifestation of metastatic prostate cancer in skin.
Urology 2006;67(2):420.
2005: Susan F Slovin; Andrew Wilton; Glenn Heller; Howard I Scher
Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8669-73.
2005: Michael J Morris; Chaitanya R Divgi; Neeta Pandit-Taskar; Maria Batraki; Nyasha Warren; Angelo Nacca; Peter Smith-Jones; Lawrence H Schwartz; W Kevin Kelly; Susan F Slovin; David B Solit; Jennifer Halpern; Anthony Delacruz; Tracy Curley; Ronald Finn; Joseph A O'Donoghue; Philip O Livingston; Steven M Larson; Howard I Scher
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7454-61.
2005: Susan F Slovin
Prostate-specific membrane antigen vaccines: naked DNA and protein approaches.
Clinical prostate cancer 2005;4(2):118-23.
2005: Kathleen W Beekman; Mark T Fleming; Howard I Scher; Susan F Slovin; Nicole Ishill; Glenn Heller; W Kevin Kelly
Second-line chemotherapy for prostate cancer: patient characteristics and survival.
Clinical prostate cancer 2005;4(2):86-90.
2005: Susan F Slovin
Fifth International Prostate Cancer Congress. 1-3 July 2005, Rio Grande, Puerto Rico.
IDrugs : the investigational drugs journal 2005;8(9):710-2.
2005: Susan F Slovin; Stacy J Keding; Govind Ragupathi
Carbohydrate vaccines as immunotherapy for cancer.
Immunology and cell biology 2005;83(4):418-28.
2005: Susan F Slovin; Govind Ragupathi; Cristina Musselli; Celina Fernandez; Meghan Diani; David Verbel; Samuel J Danishefsky; Philip O Livingston; Howard I Scher
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Cancer immunology, immunotherapy : CII 2005;54(7):694-702.
2005: Susan F Slovin
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.
Expert opinion on therapeutic targets 2005;9(3):561-70.
2005: Susan F Slovin; Govind Ragupathi; Celina Fernandez; Matthew P Jefferson; Meghan Diani; Andrew Wilton; Shemeeakah Powell; Maria A Spassova; Celso Reis; Henrik Clausen; Samuel J Danishefsky; Philip O Livingston; Howard I Scher
A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.
Vaccine 2005;23(24):3114-22.
2005: Kathleen Beekman; Michael J Morris; Susan F Slovin; Glenn Heller; Andrew Wilton; Fernando Bianco; Peter T Scardino; Howard I Scher
Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
Urology 2005;65(5):947-52.
2005: Michael J Morris; Timothy Akhurst; Steven M Larson; Marisa Ditullio; Elaina Chu; Karen Siedlecki; David Verbel; Glenn Heller; W Kevin Kelly; Susan F Slovin; Lawrence H Schwartz; Howard I Scher
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3210-6.
2005: Michael J Morris; Carlos Cordon-Cardo; W Kevin Kelly; Susan F Slovin; Karen Siedlecki; Kevin Regan; Robert S DiPaola; Mohamed M Rafi; Neal Rosen; Howard I Scher
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2005;13(1):6-13.
2004: Susan F Slovin
Cancer immunotherapeutics meeting.
Expert opinion on investigational drugs 2004;13(12):1645-50.
2004: Matthew R Smith; Judith Manola; Donald S Kaufman; Daniel George; William K Oh; Elisabetta Mueller; Susan F Slovin; Bruce M Spiegelman; Eric Small; Philip W Kantoff
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
Cancer 2004;101(7):1569-74.
2004: Michael J Morris; Oren Smaletz; David B Solit; W Kevin Kelly; Susan F Slovin; Carlos D Flombaum; Tracy Curley; Anthony Delacruz; Lawrence H Schwartz; Martin Fleisher; Andrew Zhu; Meghan Diani; Mary Fallon; Howard I Scher
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
Cancer 2004;100(9):1868-75.
2004: Howard I Scher; Mario A Eisenberger; Anthony V D'Amico; Susan Halabi; Eric J Small; Michael J Morris; Michael W Kattan; Mack Roach; Philip W Kantoff; Kenneth Pienta; Michael A Carducci; David B Agus; Susan F Slovin; Glenn Heller; W Kevin Kelly; Paul H Lange; Daniel P Petrylak; William Berg; Celestia S Higano; George Wilding; Judd W Moul; Alan W Partin; Christopher Logothetis; Howard R Soule
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(3):537-56.
2004: Susan F Slovin; William Berg; Semra Olgac; Victor E Reuter; Howard I Scher
Chemotherapeutic response with single agent gemcitabine in metastatic Bellini duct tumor.
Cancer investigation 2004;22(5):818-21.
2003: Nancy A Dawson; Susan F Slovin
Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer.
Urology 2003;62 Suppl 1():102-18.
2003: Susan F Slovin; Govind Ragupathi; Cristina Musselli; Krystyna M Olkiewicz; David Verbel; Scott D Kuduk; Jacob B Schwarz; Dalibor Sames; Samuel J Danishefsky; Philip O Livingston; Howard I Scher
Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4292-8.
2003: David B Solit; Michael J Morris; Susan F Slovin; Tracy Curley; Lawrence H Schwartz; Steven M Larson; Michael W Kattan; Beryl Hartley-Asp; Howard I Scher; W Kevin Kelly
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
Cancer 2003;98(9):1842-8.
2003: Jedd D Wolchok; Polly D Gregor; Luke T Nordquist; Susan F Slovin; Howard I Scher
DNA vaccines: an active immunization strategy for prostate cancer.
Seminars in oncology 2003;30(5):659-66.
2003: Oren Smaletz; Matthew D Galsky; Howard I Scher; Anthony Delacruz; Susan F Slovin; Michael J Morris; David B Solit; U Davar; Lawrence H Schwartz; W Kevin Kelly
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(10):1518-24.
2003: W Kevin Kelly; Andrew X Zhu; Howard I Scher; Tracy Curley; Mary Fallon; Susan F Slovin; Lawrence H Schwartz; Steven M Larson; William Tong; Beryl Hartley-Asp; Cinzia Pellizzoni; Maurizio Rocchetti
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2098-107.
2003: Susan F Slovin
Dendritic cell vaccines--hopeful or hopeless?
Cancer investigation 2003;21(6):969-70.
2002: Susan F Slovin
Biochemical relapse in prostate cancer: is PSA promoting stress and anxiety?
MedGenMed : Medscape general medicine 2002;4(3):11.
2002: Michael J Morris; William P Tong; Carlos Cordon-Cardo; Marija Drobnjak; W Kevin Kelly; Susan F Slovin; Kathryn L Terry; Karen Siedlecki; Paul Swanson; Mohamed M Rafi; Robert S DiPaola; Neal Rosen; Howard I Scher
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):679-83.
2002: Michael J Morris; Victor E Reuter; W Kevin Kelly; Susan F Slovin; Kate Kenneson; David Verbel; Iman Osman; Howard I Scher
HER-2 profiling and targeting in prostate carcinoma.
Cancer 2002;94(4):980-6.
2001: Susan F Slovin
Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity.
Hematology/oncology clinics of North America 2001;15(3):477-96.
2001: Eric Sherman; David G Pfister; Hirsch S Ruchlin; D M Rubin; Mark Radzyner; G H Kelleher; Susan F Slovin; W Kevin Kelly; Howard I Scher
The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma.
Cancer 2001;91(4):841-53.
2001: W Kevin Kelly; Tracy Curley; Susan F Slovin; Glenn Heller; John McCaffrey; Dean F Bajorin; A Ciolino; Kevin Regan; Morton K Schwartz; Philip W Kantoff; D George; William K Oh; M Smith; D Kaufman; Eric J Small; Lawrence H Schwartz; Steven M Larson; William Tong; Howard I Scher
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(1):44-53.
2000: W Kevin Kelly; Susan F Slovin
Chemotherapy for androgen- independent prostate cancer: myth or reality.
Current oncology reports 2000;2(5):394-401.
2000: ZG Wang; Linda J Williams; XF Zhang; A Zatorski; V Kudryashov; Govind Ragupathi; Maria A Spassova; William G Bornmann; Susan F Slovin; Howard I Scher; Philip O Livingston; Kenneth O Lloyd; Samuel J Danishefsky
Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(6):2719-24.
1999: Susan F Slovin; Howard I Scher
Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center.
Seminars in oncology 1999;26(4):448-54.
1999: Susan F Slovin; Howard I Scher
Rising PSAs after primary therapy: active or passive intervention.
Seminars in urologic oncology 1999;17(3):164-73.
1999: Susan F Slovin; Govind Ragupathi; S Adluri; G Ungers; K Terry; S Kim; Maria A Spassova; William G Bornmann; Melissa Fazzari; L Dantis; Krystyna M Olkiewicz; Kenneth O Lloyd; Philip O Livingston; Samuel J Danishefsky; Howard I Scher
Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(10):5710-5.
1998: Susan F Slovin; Howard I Scher
Detectable tumor cells in the blood and bone marrow: smoke or fire?
Cancer 1998;83(3):394-8.
1998: Susan F Slovin; Howard I Scher; Chaitanya R Divgi; Victor E Reuter; George Sgouros; Malcolm A S Moore; K Weingard; R Pettengall; M Imbriaco; AM el-Shirbiny; Ronald Finn; J Bronstein; C Brett; D Milenic; Ann M Dnistrian; L Shapiro; J Schlom; Steven M Larson
Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):643-51.
1998: S Zhang; H S Zhang; Victor E Reuter; Susan F Slovin; Howard I Scher; Philip O Livingston
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):295-302.
1998: Susan F Slovin; W Kevin Kelly; Howard I Scher
Immunological approaches for the treatment of prostate cancer.
Seminars in urologic oncology 1998;16(1):53-9.
1997: W Kevin Kelly; Susan F Slovin; Howard I Scher
Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.
The Urologic clinics of North America 1997;24(2):421-31.
1996: Susan F Slovin; Philip O Livingston; Neal Rosen; Laura Sepp-Lorenzino; W Kevin Kelly; J Mendelsohn; Howard I Scher
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.
Seminars in oncology 1996;23(6 Suppl 14):41-8.
1996: W Kevin Kelly; Susan F Slovin; Howard I Scher
Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer.
Seminars in oncology 1996;23(6 Suppl 14):8-14.
1990: Susan F Slovin; H C Maguire; M J Mastrangelo
The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro.
Cancer 1990;66(12):2541-6.
1989: EF McClay; Susan F Slovin
Immunotherapeutic approaches to the treatment of bone and soft tissue sarcomas.
Seminars in oncology 1989;16(4):328-32.
1987: Susan F Slovin; R D Lackman; M J Mastrangelo
HLA-A2 in sarcomas: an immunobiologic perspective.
Transplantation 1987;43(6):923-5.
1986: Susan F Slovin; R D Lackman; S Ferrone; P E Kiely; M J Mastrangelo
Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(9):3042-8.
1985: Y Hirshaut; Susan F Slovin
Harnessing T-lymphocytes for human cancer immunotherapy.
Cancer 1985;56(6):1366-73.
1984: Susan F Slovin; W S Nichols
Epstein--Barr virus nuclear antigen in a non-Hodgkin's lymphoma.
Cancer investigation 1984;2(1):21-6.
1983: D Frisman; Susan F Slovin; I Royston; S Baird
Characterization of a monoclonal antibody that reacts with an activation antigen on human B cells: reactions on mitogen-stimulated blood lymphocytes and cells of normal lymph nodes.
Blood 1983;62(6):1224-9.
1983: Susan F Slovin; R T Schooley; D A Thorley-Lawson
Analysis of cellular immune response to EBV by using cloned T cell lines.
Journal of immunology (Baltimore, Md. : 1950) 1983;130(5):2127-32.
1983: Susan F Slovin; T T Kuberski; D A Carson; M A Catalano; E M Reitz; J H Vaughan
Antibodies to Epstein-Barr virus associated antigens in Pima Indians with and without rheumatoid arthritis.
Rheumatology international 1983;3(2):65-8.
1982: C D Tsoukas; D A Carson; S Fong; Susan F Slovin; R I Fox; J H Vaughan
Lysis of autologous Epstein-Barr virus-infected B cells by cytotoxic T lymphocytes of rheumatoid arthritis patients.
Clinical immunology and immunopathology 1982;24(1):8-14.
1982: Susan F Slovin; D M Frisman; C D Tsoukas; I Royston; S M Baird; S B Wormsley; D A Carson; J H Vaughan
Membrane antigen on Epstein--Barr virus-infected human B cells recognized by a monoclonal antibody.
Proceedings of the National Academy of Sciences of the United States of America 1982;79(8):2649-53.
1981: J L Pasquali; S Fong; C D Tsoukas; Susan F Slovin; J H Vaughan; D A Carson
Different populations of rheumatoid factor idiotypes induced by two polyclonal B cell activators, pokeweed mitogen and Epstein--Barr virus.
Clinical immunology and immunopathology 1981;21(2):184-9.
1981: Susan F Slovin; M C Glassy; T Dambaugh; M A Catalano; R A Curry; S Ferrone; E Kieff; J H Vaughan; D A Carson
Discordant expression of 2 Epstein-Barr virus-associated antigens, EBNA and RANA, in man-rodent somatic cell hybrids.
Journal of immunology (Baltimore, Md. : 1950) 1981;127(2):585-90.
1981: C D Tsoukas; R I Fox; Susan F Slovin; D A Carson; M Pellegrino; S Fong; J L Pasquali; S Ferrone; P Kung; J H Vaughan
T lymphocyte-mediated cytotoxicity against autologous EBV-genome-bearing B cells.
Journal of immunology (Baltimore, Md. : 1950) 1981;126(5):1742-6.
1981: H Milgrom; E L Palmer; Susan F Slovin; D M Morens; S D Freedman; J H Vaughan
Toxic shock syndrome or Kawasaki disease.
Annals of internal medicine 1981;94(1):138.
1981: D A Carson; J L Pasquali; C D Tsoukas; S Fong; Susan F Slovin; S K Lawrance; L Slaughter; J H Vaughan
Physiology and pathology of rheumatoid factors.
Springer seminars in immunopathology 1981;4(2):161-79.
1980: R R Pascal; Susan F Slovin
Tumor directed antibody and carcinoembryonic antigen in the glomeruli of a patient with gastric carcinoma.
Human pathology 1980;11(6):679-82.
1980: Susan F Slovin; J H Vaughan; D A Carson
Changes in the expression of two Epstein-Barr virus-associated antigens, EBNA and RANA, during the cell cycle of transformed human B lymphoblasts.
International journal of cancer. Journal international du cancer 1980;26(1):9-12.
1980: M A Catalano; Susan F Slovin; S S Freer
Anti-RANA antibody and rheumatoid arthritis.
Lancet 1980;1(8172):824.
1980: H Milgrom; E L Palmer; Susan F Slovin; D M Morens; S D Freedman; J H Vaughan
Kawasaki disease in healthy young adult.
Annals of internal medicine 1980;92(4):467-70.
1980: A N Theofilopoulos; D A Carson; M Tavassoli; Susan F Slovin; W C Speers; F B Jensen; J H Vaughan
Evidence for the presence of receptors for C3 and IgG Fc on human synovial cells.
Arthritis and rheumatism 1980;23(1):1-9.
1979: M A Catalano; D A Carson; Susan F Slovin; D D Richman; J H Vaughan
Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis.
Proceedings of the National Academy of Sciences of the United States of America 1979;76(11):5825-8.
1977: Susan F Slovin; S J Bennett; R R Pascal
Elution of tumor-directed antibody from kidneys of mammary tumor-bearing mice.
Journal of the National Cancer Institute 1977;59(5):1499-501.
1977: I Parikh; Susan F Slovin
An introduction to affinity chromatography.
Advances in pathobiology 1977;(6):263-71.